

VIA HAND DELIVERY MAY 7th, 2003

#8
LP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ni et al.

Application Serial No.: 10/041,574

Group Art Unit: 1646

Filed: January 10, 2002

Examiner: O'Hara, E.

For: Human Tumor Necrosis Factor
Receptor TR9

Atty. Docket No.: PF375P1D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BE listed on the attached Form PTO/SB/08. Legible copies of references BC-BE are enclosed herewith.

Copies of references AA-BB were submitted by Applicants in connection with United States Patent Application Serial No. 09/095,094, filed June 10, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/095,094 for copies of references AA-BB.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of the present application are related to SEQ ID NOs:100223, 108011 and 187451 in copending U.S. Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293, which

caused it to be listed on the attached form PTO/SB/08 is submitted herewith as reference BD.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of the present application are related to SEQ ID NOs:714 and 20125 in copending U.S. Application Serial No. 09/912,292. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,292, which caused it to be listed on the attached form PTO/SB/08 is submitted herewith as reference BE.


Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: May 7, 2003


Lin J. Hymel (Reg. No. 45,414)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (phone)

Enclosures
KKH/LJH/BM/lcc